Sinopharm Group Co (HK:1099) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sinopharm Group Co. Ltd. has reported a decrease in revenue and net profit for Sinopharm Accord, its subsidiary, in the first half of 2024 compared to the same period last year, with revenue down by 1.57% and net profit by over 10%. Additionally, there was a significant 37.47% drop in net cash flow from operating activities. Despite these declines, total assets saw an increase of 8.06%.
For further insights into HK:1099 stock, check out TipRanks’ Stock Analysis page.